

MEDTECS INTERNATIONAL CORPORATION LIMITED

(Incorporated in Bermuda)

CHANGES TO THE COMPOSITION OF THE BOARD OF DIRECTORS AND BOARD COMMITTEES OF MEDTECS INTERNATIONAL CORPORATION LIMITED ("COMPANY")

The Board of Directors (the "Board") of the Company wishes to announce the following:

(1) Retirement of Lead Independent Director

Mr Lim Tai Toon, who did not seek re-election at the annual general meeting of the Company held on 30 April 2024 ("**AGM**"), has retired as the Lead Independent Director at the conclusion of the AGM and accordingly has ceased to be the Chairman of the Audit Committee and a member of each of the Nominating Committee and Remuneration Committee.

The Company would like to express its gratitude to Mr Lim for his contributions and dedicated service as our Lead Independent Director and Chairman of the Audit Committee over the past 14 years. His wise counsel and unwavering commitment to good corporate governance have been instrumental in guiding the Company's growth and success throughout his tenure. On behalf of the Board and management, we thank Mr Lim for his contributions and wish him all the best in his future endeavors.

The particulars in relation to his retirement as required pursuant to Rule 704(6) of the Singapore Exchange Securities Trading Limited Listing Manual Section B: Rules of Catalist ("Catalist Rules") have been released today as a separate announcement via SGXNET.

(2) Retirement of Independent Director

Ms Carol Yang Xiao-Qing, who did not seek re-election at the annual general meeting of the Company held on 30 April 2024 ("**AGM**"), has retired as an Independent Director at the conclusion of the AGM and accordingly has ceased to be the Chairman of the Nominating Committee and a member of each of the Audit Committee and Remuneration Committee.

Throughout her 19 years of dedicated service, Carol has been a valuable asset to the Board, especially in her role as Chairman of the Nominating Committee. Her leadership and commitment to maintaining a strong Board composition have contributed to Medtecs' success. The Company is grateful for her efforts and the significant contributions she has made during her tenure with the Company, both as an Independent Director and as a member of various committees.

The particulars in relation to her retirement as required pursuant to Rule 704(6) of the Catalist Rules has been released today as a separate announcement via SGXNET.

(3) Appointment of Independent Directors

Following the retirement of Ms Carol Yang Xiao-Qing and Mr Lim Tai Toon at the AGM, the Board has upon the conclusion of the AGM appointed:

- (a) Ms Jessie Low Mui Choo ("**Ms Jessie Low**") as the Lead Independent Non-Executive Director of the Company. Ms Jessie Low shall also be appointed as the Chairman of the Audit Committee and a member of each of the Nominating Committee and Remuneration Committee; and
- (b) Ms Yuhong Zhao as an Independent Non-Executive Director of the Company. Ms Yuhong Zhao shall also be appointed as the Chairman of the Nominating Committee and a member of each of the Audit Committee and Remuneration Committee.

The particulars in relation to the appointments of Ms Jessie Low and Ms Yuhong Zhao as required pursuant to Rule 704(6) of the Catalist Rules have been released today as separate announcements via SGXNET.

Following the above changes, the composition of the Board and its committees with effect from 30 April 2024 shall be as follows:

(A) Board of Directors

Mr Clement Yang Ker-Cheng (Chairman, Executive Director)
Mr William Yang Weiyuan (Deputy Chairman, Executive Director and CEO)
Ms Jessie Low Mui Choo (Lead Independent Director)
Dr Nieh Chien-Chung (Independent Director)
Ms Yuhong Zhao (Independent Director)

(B) Audit Committee

Ms Jessie Low Mui Choo (Chairman) Ms Yuhong Zhao Dr Nieh Chien-Chung

(C) Nominating Committee

Ms Yuhong Zhao (Chairman) Mr Clement Yang Ker-Cheng Mr William Yang Weiyuan Dr Nieh Chien-Chung Ms Jessie Low Mui Choo

(D) Remuneration Committee

Dr Nieh Chien-Chung (Chairman)
Ms Jessie Low Mui Choo
Ms Yuhong Zhao

Submitted by Mr Clement Yang, Executive Chairman on 30 April 2024 to the SGX-ST.

This document has been prepared by the Company and its contents have been reviewed by the Company's sponsor, R & T Corporate Services Pte. Ltd. ("**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**Exchange**").

This document has not been examined or approved by the Exchange. The Exchange assumes no responsibility for the contents of this document including the correctness of any of the statements or opinions made or reports contained in this document.

The contact persons for the Sponsor are Ms Evelyn Wee (Telephone Number: +65 6232 0724) and Mr. Howard Cheam Heng Haw (Telephone Number: +65 6232 0685), R & T Corporate Services Pte. Ltd., at 9 Straits View, Marina One West Tower, #06-07 Singapore 018937.